| abstract |
The invention generally relates to monoclonal antibodies recognizing CD47, and more particularly to anti-CD47 antibodies that do not cause significant agglutination of the cells, to methods for producing such antibodies and to methods of using these monoclonal antibodies as therapeutic agents. |